JP2011509937A5 - - Google Patents

Download PDF

Info

Publication number
JP2011509937A5
JP2011509937A5 JP2010542381A JP2010542381A JP2011509937A5 JP 2011509937 A5 JP2011509937 A5 JP 2011509937A5 JP 2010542381 A JP2010542381 A JP 2010542381A JP 2010542381 A JP2010542381 A JP 2010542381A JP 2011509937 A5 JP2011509937 A5 JP 2011509937A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
compound
optionally substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010542381A
Other languages
English (en)
Japanese (ja)
Other versions
JP5501251B2 (ja
JP2011509937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/030646 external-priority patent/WO2009089482A1/en
Publication of JP2011509937A publication Critical patent/JP2011509937A/ja
Publication of JP2011509937A5 publication Critical patent/JP2011509937A5/ja
Application granted granted Critical
Publication of JP5501251B2 publication Critical patent/JP5501251B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010542381A 2008-01-11 2009-01-09 Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類 Active JP5501251B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2053008P 2008-01-11 2008-01-11
US61/020,530 2008-01-11
US4867708P 2008-04-29 2008-04-29
US61/048,677 2008-04-29
PCT/US2009/030646 WO2009089482A1 (en) 2008-01-11 2009-01-09 (1-azinone) -substituted pyridoindoles as mch antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014047896A Division JP2014129417A (ja) 2008-01-11 2014-03-11 Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類

Publications (3)

Publication Number Publication Date
JP2011509937A JP2011509937A (ja) 2011-03-31
JP2011509937A5 true JP2011509937A5 (enExample) 2012-02-23
JP5501251B2 JP5501251B2 (ja) 2014-05-21

Family

ID=40429805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010542381A Active JP5501251B2 (ja) 2008-01-11 2009-01-09 Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
JP2014047896A Pending JP2014129417A (ja) 2008-01-11 2014-03-11 Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014047896A Pending JP2014129417A (ja) 2008-01-11 2014-03-11 Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類

Country Status (13)

Country Link
US (4) US8716308B2 (enExample)
EP (2) EP2240481A1 (enExample)
JP (2) JP5501251B2 (enExample)
KR (1) KR101614723B1 (enExample)
CN (1) CN101945872B (enExample)
AU (1) AU2009204048B2 (enExample)
BR (1) BRPI0907122B8 (enExample)
CA (1) CA2727055C (enExample)
ES (1) ES2523580T3 (enExample)
IL (1) IL206594A (enExample)
MX (1) MX2010007430A (enExample)
NZ (1) NZ586120A (enExample)
WO (1) WO2009089482A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240481A1 (en) * 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US9187455B2 (en) * 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) * 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
EP2802571A1 (en) * 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
WO2020116296A1 (ja) 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
CN114901279A (zh) * 2019-03-13 2022-08-12 洛克菲勒大学 用于治疗自身炎性疾病和癌症转移的cGAS的抑制剂
EP4076527A4 (en) * 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
EP4155299A4 (en) 2020-05-19 2024-07-10 Unimatec Co., Ltd. Fluoropyrimidine compound and fluoropyrimidinone compound
KR20230152692A (ko) * 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
CN118251386A (zh) 2021-11-12 2024-06-25 优迈特株式会社 含氟嘧啶化合物、有害菌类防除剂和含氟嘧啶化合物的制造方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3514462A (en) 1966-10-21 1970-05-26 Upjohn Co 1 and 2 ethoxy 3,4,5,10 - tetrahydroazepino(3,4-b) and (2,3-b)indoles and corresponding amino derivatives thereof
CH649553A5 (de) 1982-05-06 1985-05-31 Sandoz Ag Azepinoindole und verfahren zu deren herstellung.
EP0318492A1 (en) 1986-08-11 1989-06-07 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
IT1223343B (it) 1987-11-03 1990-09-19 Also Lab Sas Formulazioni farmaceutiche per somministrazione transdermica
JPH0256485A (ja) 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
HU207078B (en) 1988-08-02 1993-03-01 Glaxo Group Ltd Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
CA2050905A1 (en) 1989-02-23 1990-08-24 George R. Felt Therapeutic aerosol formulations
GB8904551D0 (en) 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
US4978669A (en) 1989-06-08 1990-12-18 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
US5169852A (en) 1989-06-08 1992-12-08 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
CA2036337C (fr) 1990-02-15 2003-04-15 Francois Clemence Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
US5225407A (en) 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5162336A (en) 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5187180A (en) 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
JP2951434B2 (ja) 1991-04-18 1999-09-20 三菱製紙株式会社 電子写真感光体
DE4130933A1 (de) 1991-09-13 1993-03-18 Schering Ag Neue (beta)-carbolinderivate, deren herstellung und verwendung in arzneimitteln
DE4240672A1 (de) 1992-11-24 1994-05-26 Schering Ag Neues Verfahren zur Herstellung von beta-Carbolinen
IL109220A0 (en) 1993-04-05 1994-07-31 Synaptic Pharma Corp Dihydropyridines and new uses thereof
US5767131A (en) 1993-04-05 1998-06-16 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
GB9418326D0 (en) 1994-09-12 1994-11-02 Lilly Industries Ltd Pharmaceutical compounds
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5466688A (en) 1994-10-20 1995-11-14 American Home Products Corporation Pyrido[3,4-B]indole derivatives as serotonergic agents
AU3831495A (en) 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
EP0801557B1 (en) 1995-10-12 2003-07-02 Supergen, Inc. Liposome formulations of 5beta steroids
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
JP2000505471A (ja) 1996-02-28 2000-05-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲン受容体拮抗物質
US5932582A (en) 1996-06-28 1999-08-03 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
EP0912175A4 (en) 1996-06-28 1999-09-08 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS
EP0912513A1 (en) 1996-06-28 1999-05-06 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5811551A (en) 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US6713645B1 (en) 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
PL193450B1 (pl) 1998-03-17 2007-02-28 Besins Iscovesco Lab Pochodne beta-karboliny, sposób ich wytwarzania, zawierający je produkt medyczny oraz zastosowanie pochodnych beta-karboliny
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
CN1310612A (zh) 1998-05-20 2001-08-29 利普索姆公司 新型颗粒制剂
ATE318818T1 (de) 1998-06-16 2006-03-15 Us Gov Health & Human Serv Annellierte azepinone als inhibitoren cyclin- abhängiger kinasen
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
EP1142870A1 (en) 1998-12-14 2001-10-10 Nuclear Receptor Research Limited Novel ligands of nuclear receptor
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
EP1338272A1 (en) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
KR100845769B1 (ko) 1999-02-03 2008-07-11 파우더젝트 리서치 리미티드 하이드로겔 입자 제제
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
NZ513981A (en) 1999-03-08 2004-02-27 Powderject Res Ltd Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
WO2000062759A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6548493B1 (en) 1999-06-15 2003-04-15 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
ES2220724T3 (es) 2000-01-20 2004-12-16 Basilea Pharmaceutica Ag Composiciones de peptidos ciclicos administrables por via nasal.
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5261594A1 (es) 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
JP5000828B2 (ja) 2000-03-15 2012-08-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＩｋＢキナーゼ阻害活性を有する置換ベーターカルボリン
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
ATE364381T1 (de) 2000-04-17 2007-07-15 Vectura Ltd Formulierungen zur verwendung in inhalationsvorrichtungen
WO2001087883A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
EP1294752A2 (en) 2000-06-16 2003-03-26 Curis, Inc. Angiogenesis-modulating compositions and uses
AU2001269781A1 (en) 2000-07-06 2002-01-21 Pharmacia And Upjohn Company Substituted 2,3,7,8,9,10,11,12-octahydroazepino(4,5-b)pyrano(3,2-e) indoles
US6586421B2 (en) 2000-09-20 2003-07-01 Pharmacia & Upjohn Company Substituted azepino[4,5b]indoline derivatives
CA2423308A1 (en) 2000-10-02 2002-04-11 Lilly Icos Llc Condensed pyridoindole derivatives
MXPA03002911A (es) 2000-10-03 2003-09-10 Lilly Icos Llc Compuestos quimicos.
FI20002768L (fi) 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
BR0116429A (pt) 2000-12-20 2006-05-09 Bristol Myers Squibb Co piridoindóis substituìdos como agonistas e antagonistas da serotonina
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US6780862B2 (en) 2000-12-20 2004-08-24 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
US7122554B2 (en) 2001-02-12 2006-10-17 Lilly Icos Llc. Carboline derivatives
ES2248412T3 (es) 2001-02-12 2006-03-16 Lilly Icos Llc Derivados de carbolina.
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
US7115621B2 (en) 2001-04-25 2006-10-03 Lilly Icos Llc Chemical compounds
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
US6992192B2 (en) 2001-06-05 2006-01-31 Lilly Icos Llc. Carboline derivatives as PDE5 inhibitors
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
BR0211608A (pt) 2001-08-08 2006-04-04 Upjohn Co 1h-pirido[4,3-b]indóis terapêuticos
PT1418890E (pt) 2001-08-16 2008-06-09 Baxter Int Formulações de micropartículas à base de propulsor
EP2329822A1 (en) 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
AU2003215334A1 (en) 2002-02-22 2003-09-09 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
EP1487411B1 (en) 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalable sustained therapeutic formulations
AU2003233118B8 (en) 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
US6951881B2 (en) 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6906095B2 (en) 2002-05-10 2005-06-14 Wyeth Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
AU2003277215A1 (en) 2002-10-01 2004-04-23 Predix Pharmaceuticals Holdings, Inc. Novel neurokinin antagonists and methods of use thereof
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0305553D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Compounds
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
WO2004103958A2 (en) 2003-05-19 2004-12-02 Michigan State University Preparation of hymenialdisine derivatives and use thereof
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7332520B2 (en) 2003-06-06 2008-02-19 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060235012A1 (en) 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
EP1650206A4 (en) 2003-08-01 2006-12-20 Nippon Soda Co PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005206570A1 (en) 2004-01-23 2005-08-04 Novartis Vaccines And Diagnostics, Inc. Tetrahydrocarboline compounds as anticancer agents
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
JP4734119B2 (ja) 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US20050187387A1 (en) * 2004-02-25 2005-08-25 Lynch John K. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7705017B2 (en) 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
UA87313C2 (ru) 2004-05-12 2009-07-10 Байер Кропсайенс Аг Применение производного конденсированного азепинона для регулирования роста растений, композиция на его основе и способ регулирования роста растений
US20070254877A1 (en) 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer
EP1786425A1 (en) 2004-08-02 2007-05-23 SmithKline Beecham Corporation Useful compounds for hpv infection
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
EA014956B1 (ru) 2004-12-17 2011-04-29 ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений
US20060167259A1 (en) 2005-01-21 2006-07-27 Cephalon, Inc. Direct racemization of indole derivatives
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
WO2006089874A1 (en) 2005-02-22 2006-08-31 Gpc Biotech Ag Benzo[2,3]azepino[4,5-b]indol-6-ones
DE102005016460A1 (de) 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
ATE542535T1 (de) 2005-05-04 2012-02-15 Develogen Ag Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
CN101213190A (zh) 2005-07-14 2008-07-02 Irm责任有限公司 用作tpo模拟物的化合物和组合物
WO2007016353A2 (en) 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
RU2008108903A (ru) 2005-08-12 2009-09-20 Джинентех, Инк. (US) Пентациклический ингибитор киназы
EP1757607A1 (en) 2005-08-24 2007-02-28 Molisa GmbH N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases
JPWO2007024004A1 (ja) * 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
MX2008003202A (es) 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
JP2009508966A (ja) 2005-09-23 2009-03-05 シェーリング コーポレイション 治療薬としての縮合四環性ｍＧｌｕＲ１アンタゴニスト
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
WO2007070796A1 (en) 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2007120333A2 (en) 2005-12-16 2007-10-25 Genentech, Inc. Tetracyclic kinase inhibitors
CN101341135B (zh) 2005-12-21 2013-08-14 詹森药业有限公司 治疗mch-1介导的疾病的取代的吡嗪酮衍生物
RU2008145225A (ru) 2006-04-19 2010-05-27 Новартис АГ (CH) Соединения индазола и способы ингибирования cd7
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080124319A1 (en) 2006-05-16 2008-05-29 Charalabos Pothoulakis Methods for treating inflammation by disrupting MCH-mediated signaling
EP2018380B1 (en) 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
UY30378A1 (es) * 2006-06-02 2008-01-02 Janssen Pharmaceutica Nv Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1
WO2007142217A1 (ja) 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. １－フェニルピリドン誘導体
CN101074207B (zh) 2006-06-08 2014-03-26 中国科学院成都有机化学有限公司 一类水溶性的手性二胺衍生物及其应用和制备
CN101108859A (zh) 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
RU2317989C1 (ru) 2006-08-24 2008-02-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2453543C2 (ru) * 2006-08-25 2012-06-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые производные пиридона, обладающие антагонистической активностью в отношении mch, и лекарственные средства, включающие такие соединения
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
WO2008046155A1 (en) 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
MX2009005908A (es) * 2006-12-05 2009-06-16 Janssen Pharmaceutica Nv Derivados novedosos de diaza-espiro-piridinona sustituidos para usarse en las enfermedades mediadas por la hormona concentradora de melanina 1.
WO2008081282A2 (en) 2006-12-20 2008-07-10 Glenmark Pharmaceuticals S.A. Process for the synthesis of n9-(3,5-dichloro-4-pyridyl)-6- difluoromethoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide and salts thereof
US8268868B2 (en) 2007-01-10 2012-09-18 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
JP2010515745A (ja) 2007-01-10 2010-05-13 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−フロピリジノン置換インダゾール
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
DE102007009319A1 (de) 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009235A1 (de) 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US8063089B2 (en) 2007-02-28 2011-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
TW200902016A (en) 2007-05-22 2009-01-16 Taigen Biotechnology Co Ltd Kinesin inhibitors
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
KR20100040872A (ko) 2007-06-25 2010-04-21 뉴로젠 코포레이션 피페라지닐 옥소알킬 테트라하이드로-베타-카르볼린 및 이의 관련 유사체
WO2009001129A1 (en) 2007-06-26 2008-12-31 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors
EP2176251B1 (en) 2007-07-21 2012-02-08 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles and pharmaceutical compositions thereof
WO2009022104A1 (en) 2007-08-13 2009-02-19 De Montfort University Fascaplysin derivatives and their use in the treatment of cancer
CA2597193A1 (en) 2007-08-13 2009-02-13 De Montfort University Compounds and uses
MX2010002316A (es) 2007-08-29 2010-03-22 Schering Corp Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
EP2240481A1 (en) * 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof

Similar Documents

Publication Publication Date Title
JP2011509937A5 (enExample)
JP6218260B2 (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
JP6385954B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
JP2012501312A5 (enExample)
JP2013523884A5 (enExample)
AU2019283921A1 (en) Indole carboxamide compounds useful as kinase inhibitors
JP2018524331A5 (enExample)
AU2015276264B2 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
JP2011523945A5 (enExample)
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP2016539146A5 (enExample)
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
JP2017518326A5 (enExample)
JP2018505903A5 (enExample)
AU2021207804A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
EP3209665A1 (en) Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
JP2011529959A5 (enExample)
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
JP2013518823A5 (enExample)
WO2015164520A4 (en) Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c] pyridine compounds as glyt1 inhibitors
JP2020531487A5 (enExample)
AU2023305453A1 (en) Tyrosine kinase 2 inhibitors and uses thereof
JPWO2023046117A5 (enExample)
RU2024111199A (ru) Ингибиторы fgfr и способы их применения